Suppression of XXXX by @entity6237 , a new antiarrhythmic agent.

@entity6237 @entity1 @entity943 @entity1540
@entity6237 , a new antiarrhythmic agent, was given orally to 11 hospitalized @entity1 with chronic high-frequency @entity1540 . Drug effectiveness was evaluated with a dose-ranging single-blind protocol, which included placebo control and washout periods. Twice-daily dosing (average daily dose 436 mg) completely suppressed all @entity1540 activity in five of 11 @entity1 ; average suppression in the 11 @entity1 was 96.3%. Complex @entity943 , which were present in all 11 @entity1 during the placebo control period, were completely suppressed in eight @entity1 and markedly suppressed in the other three @entity1 during @entity6237 therapy. Ejection fraction and velocity of circumferential fiber shortening measured by M-mode echocardiography did not change significantly during @entity6237 dosing. @entity943 returned in all @entity1 during the placebo washout period. During subsequent outpatient therapy with @entity6237 , significant suppression was present after 1 and 2 weeks of treatment (94.4% and 93.3%, respectively). Drug elimination was slow (average plasma half-life 20 hours). Ninety-five percent suppression of @entity1540 during dosing and 5% reappearance of @entity943 during washout occurred with @entity6237 concentrations of 200-800 ng/ml. Side effects occurred in five of 11 @entity1 , but did not require discontinuation of the drug. These results indicate that @entity6237 is a very effective antiarrhythmic agent that merits further clinical investigation.
